* Adicet Bio Inc is expected to show no change in quarterly revenue when it reports results on November 6 (estimated) for the period ending January 1 0001
*
* LSEG's mean analyst estimate for Adicet Bio Inc is for a loss of 34 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Adicet Bio Inc is $7.00, above its last closing price of $1.25.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.36 -0.36 -0.33 Beat 9.3
Jan. 1 2024 -0.38 -0.39 -0.35 Beat 9.7
Dec. 31 2023 -0.72 -0.69 -0.69 Met 0.6
Jan. 1 0001 -0.78 -0.74 -1.16 Missed -57.3
Jan. -0.71 -0.68 -0.75 Missed -10
1 0001
Mar. 31 2023 -0.71 -0.69 -0.72 Missed -4.8
Dec. 31 2022 0.29 -0.28 -0.72 Missed -158.1
Sep. 30 2022 -0.55 -0.53 -0.53 Met -0.6
This summary was machine generated November 4 at 22:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。